Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICONIC-UC: Icotrokinra in Moderately to Severely Active Ulcerative Colitis
jRCT2071250074Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2025
- Modality
- Peptides
01
Overview
Phase 3, randomised, double-blind trial of icotrokinra in autoimmune colitis (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: DB Induction: Clinical Remission at Week I-12 (Adults), DB Maintenance: Clinical Remission at Week M-40 (Adults) and 1 more. Started Oct 2025; status: active, not recruiting.
02
Drugs
icotrokinra
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2071250074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250074.